E. Mcmahon

发表

Effects of Long-Term Monotherapy With Eplerenone, a Novel Aldosterone Blocker, on Progression of Left Ventricular Dysfunction and Remodeling in Dogs With Heart Failure

Sidney Goldstein, Hani N Sabbah, S. Goldstein, 2002, Circulation.

Development and comparison of two 3T3-L1 adipocyte models of insulin resistance: increased glucose flux vs glucosamine treatment.

E. Gulve, S. Ross, X. Chen, 2000, Biochemical and biophysical research communications.

The Antioxidant, N-(2-mercaptopropionyl)-glycine (MPG), Does Not Reduce Myocardial Infarct Size in an Acute Canine Model of Myocardial Ischemia and Reperfusion

C. Venturini, Mark E. Smith, E. Mcmahon, 1998, Journal of Thrombosis and Thrombolysis.

Conformationally restricted polysubstituted biphenyl derivatives with angiotensin II receptors antagonist properties.

W C Hutton, E G McMahon, W. Hutton, 1991, Journal of medicinal chemistry.

Effects of SC-52458, an angiotensin AT1 receptor antagonist, in the dog.

P. Yang, C. Cook, E. Mcmahon, 1997, American journal of hypertension.

In vitro and in vivo activity of chymotrypsin-activated big endothelin (porcine 1-40).

W. M. Moore, C. E. Smith, N. Siegel, 1989, Biochemical and biophysical research communications.

Stimulatory effect of lithium on glucose transport in rat adipocytes is not mediated by elevation of IP1.

E. Gulve, E. Mcmahon, Xiaoli Chen, 1998, American journal of physiology. Endocrinology and metabolism.

Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits.

E. H. Blaine, D. Blehm, E. Mcmahon, 1993, The Journal of clinical investigation.

Eplerenone, Pharmacological Effects of

A. Rudolph, R. Rocha, E. Mcmahon, 2003 .

Phosphoramidon blocks the pressor activity of big endothelin[1-39] and lowers blood pressure in spontaneously hypertensive rats.

W. M. Moore, E. Mcmahon, M. Palomo, 1991, Journal of cardiovascular pharmacology.

Phosphoramidon blocks the pressor activity of porcine big endothelin-1-(1-39) in vivo and conversion of big endothelin-1-(1-39) to endothelin-1-(1-21) in vitro.

W. M. Moore, E. Mcmahon, M. Palomo, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Expression, purification, and in vivo activity of atrial natriuretic factor prohormone produced in Escherichia coli.

C. S. Devine, J. Gierse, P. O. Olins, 1989, Archives of biochemistry and biophysics.

Role of endothelin and prostaglandins in radiocontrast-induced renal artery constriction.

Jeffrey S. Carter, L. Cantley, F. Epstein, 1993, Kidney international.

In vitro pharmacology of a nonpeptidic angiotensin II receptor antagonist, SC-51316.

D. Reitz, V. Corpus, E. H. Blaine, 1992, The Journal of pharmacology and experimental therapeutics.

Vasorelaxant effects of atriopeptins in human internal mammary artery.

E. Mcmahon, W. Marshall, 1988, European Journal of Pharmacology.

Increased activity of the hexosamine synthesis pathway in muscles of insulin-resistant ob/ob mice.

M. Buse, E. Gulve, T. Gettys, 1997, The American journal of physiology.

Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats.

E. Blasi, E. Blomme, A. Rudolph, 2003, Kidney international.

Central and Peripheral Actions of a Nonpeptidic Angiotensin II Receptor Antagonist

D. Reitz, E. H. Blaine, A. Trapani, 1990, Hypertension.

Effect of phosphoramidon (endothelin converting enzyme inhibitor) and BQ-123 (endothelin receptor subtype A antagonist) on blood pressure in hypertensive rats.

S. Bertenshaw, M. Brown, E. Mcmahon, 1993, American journal of hypertension.

Nonpeptide angiotensin II antagonists: N-phenyl-1H-pyrrole derivatives are angiotensin II receptor antagonists.

E G McMahon, J. Collins, D. Reitz, 1993, Journal of medicinal chemistry.

Phosphorus-containing inhibitors of endothelin converting enzyme: effects of the electronic nature of phosphorus on inhibitor potency.

R. S. Rogers, S. Bertenshaw, B. Norman, 1993, Journal of medicinal chemistry.

The evolution of aldosterone antagonists

Susan M Garthwaite, Ellen G McMahon, S. Garthwaite, 2004, Molecular and Cellular Endocrinology.

Aldosterone induces a vascular inflammatory phenotype in the rat heart.

Ricardo Rocha, Eric A G Blomme, E. Blomme, 2002, American journal of physiology. Heart and circulatory physiology.

Structural, functional, and molecular characterization of the SHHF model of heart failure.

E. Blasi, K. Nikula, J. V. Van Vleet, 2002, American journal of physiology. Heart and circulatory physiology.

Eplerenone, a new selective aldosterone blocker.

E. Mcmahon, 2003, Current pharmaceutical design.

Chapter 70 – Mineralocorticoid Receptor Antagonists

E. Mcmahon, 2005 .

Prostate Effect in Dogs with the Aldosterone Receptor Blocker Eplerenone

R. R. Bell, A. John-Baptiste, E. Mcmahon, 2013, Toxicologic pathology.

Aldosterone target organ protection by eplerenone

A. Rudolph, R. Rocha, E. Mcmahon, 2004, Molecular and Cellular Endocrinology.

Transgenic Model of Aldosterone-Driven Cardiac Hypertrophy and Heart Failure

J. Goellner, E. Blomme, J. Funder, 2003, Circulation research.

Emerging therapies for heart failure

A. Rudolph, E. Mcmahon, 2002, Expert opinion on emerging drugs.

Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.

E. Mcmahon, Ellen G. Mcmahon, 2001, Current opinion in pharmacology.

Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart.

J. Delyani, R. Rocha, E. Mcmahon, 2002, Endocrinology.

Depressor and natriuretic effects of M&B 22,948, a guanosine cyclic 3',5'-monophosphate-selective phosphodiesterase inhibitor.

P. Mehta, E. Mcmahon, G. M. Olins, 1989, The Journal of pharmacology and experimental therapeutics.

N1-sterically hindered 2H-imidazol-2-one angiotensin II receptor antagonists: The conversion of surmountable antagonists to insurmountable antagonists

K. Koehler, J. Collins, D. J. Garland, 1993 .

Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor.

E. H. Blaine, A. Trapani, G. Smits, 1991, The Journal of pharmacology and experimental therapeutics.

Pharmacology of SC‐52458, an Orally Active, Nonpeptide Angiotensin AT1 Receptor Antagonist

R. Schmidt, D. Reitz, V. Corpus, 1993, Journal of cardiovascular pharmacology.

Effect of endothelinA-receptor antagonist BQ-123 and phosphoramidon on cerebral vasospasm.

F. Cosentino, E. Mcmahon, J. Carter, 1993, Journal of cardiovascular pharmacology.

A carboxy-terminus truncated analogue of angiotensin II, [Sar1]angiotensin II-(1-7)-amide, provides an entry to a new class of angiotensin II antagonists.

A. Trapani, E. Mcmahon, P. Bovy, 1989, Journal of medicinal chemistry.

Conformational restriction of angiotensin II: cyclic analogues having high potency.

E G McMahon, E. Reinhard, E J Reinhard, 1990, Journal of medicinal chemistry.

Synthesis and structure-activity relationships of nonpeptide, potent triazolone-based angiotensin II receptor antagonists.

D. Reitz, V. Corpus, J. P. Koepke, 1993, Journal of medicinal chemistry.

Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.

X. Hu, Suzhen Li, D. Lala, 2005, Mini reviews in medicinal chemistry.

Synthesis and biological activity of N-terminus modified [Ile8] angiotensin II analogues

E. Mcmahon, M. Palomo, D. E. Mcgraw, 1990 .